

Applicant: Erik Buntinx  
Serial No.: 10/803,793  
Filed: March 18, 2004  
page 2 of 24

Amendments to the Specification:

Please replace the current Abstract with the Abstract attached hereto on a separate sheet. A marked-up version of the Abstract showing the changes made is also attached hereto.

On page 30, between paragraphs [00124] and [00125], please amend the header for Example 2 as follows:

Example 2: Foregoing pipamperone-citalopram treatment in mayor depressive disorder: a placebo and active controlled period finding clinical trial.

On pages 30-31, please amend paragraph [00125] as follows:

[00125] Table 2 represents the set-up of a clinical trial comprising for treatment groups:

Group Plc – Active / Day 0 represents the group receiving 10 mg citalopram, twice a day, starting the first day (Day 0) of active treatment in the clinical trial. This administration regime is also indicated as the mono therapy.

Group Pip - Active / Day 0 represents the group receiving a combination of 4 mg pipamperone and 10 mg citalopram, twice a day, starting the first day (Day 0) of active treatment in the clinical trial. This administration regime is also indicated as the non-foregoing combo therapy.

Group Pip - Active / Day 4 represents the group receiving 4 mg pipamperone, twice a day, starting the first day (Day 0) of active treatment in the clinical trial, followed by a combination of 4 mg pipamperone and 10 mg citalopram, twice a day, starting the fifth (Day 4) day of active treatment in the clinical trial. This administration regime is also indicated as the foregoing therapy with combination therapy starting after 4 days of active treatment.

Applicant: Erik Buntinx  
Serial No.: 10/803,793  
Filed: March 18, 2004  
page 3 of 24

Group Pip - Active / Day 7 represents the group receiving 4 mg pipamperone, twice a day, starting the first day (Day 0) of active treatment in the clinical trial, followed by a combination of 4 mg pipamperone and 10 mg citalopram, twice a day, starting the eighth (Day 7) day of active treatment in the clinical trial. This administration regime is also indicated as the foregoing therapy with combination therapy starting after 7 days of active treatment.

On page 31, between paragraphs [00128] and [00129], please amend the header for Example 3 as follows:

Example 3: Foregoing pipamperone-pergolide treatment in Parkinson Disease: a placebo and active controlled period finding clinical trial.

On pages 31-32, please amend paragraph [00129] as follows:

[00129] Table 3 represents the set-up of a clinical trial comprising for treatment groups:

Group Plc – Active / Day 0 represents the group receiving 1.5 mg pergolide, twice a day, starting the first day (Day 0) of active treatment in the clinical trial. This administration regime is also indicated as the mono therapy.

Group Pip - Active / Day 0 represents the group receiving a combination of 4 mg pipamperone and 1.5 mg pergolide, twice a day, starting the first day (Day 0) of active treatment in the clinical trial. This administration regime is also indicated as the non-foregoing combo therapy.

Group Pip - Active / Day 4 represents the group receiving 4 mg pipamperone, twice a day, starting the first day (Day 0) of active treatment in the clinical trial, followed by a combination of 4 mg pipamperone and 1.5 mg pergolide, twice a day, starting the fifth (Day 4) day of active treatment in the clinical trial. This administration regime is also

Applicant: Erik Buntinx  
Serial No.: 10/803,793  
Filed: March 18, 2004  
page 4 of 24

indicated as the foregoing therapy with combination therapy starting after 4 days of active treatment.

Group Pip - Active / Day 7 represents the group receiving 4 mg pipamperone, twice a day, starting the first day (Day 0) of active treatment in the clinical trial, followed by a combination of 4 mg pipamperone and 1.5 mg pergolide, twice a day, starting the eighth (Day 7) day of active treatment in the clinical trial. This administration regime is also indicated as the foregoing therapy with combination therapy starting after 7 days of active treatment.